A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT05121948 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped sponsor decision

Conditions

Squamous Cell Carcinoma of Head and Neck
Colo-rectal Cancer
Non Small Cell Lung Cancer
Transitional Cell Carcinoma of the Bladder
Other Solid Tumors
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: HC-7366

Sponsor

HiberCell, Inc.

Collaborators

[object Object]